LONDON (ShareCast) - (Sharecast News) - Boston Scientific has agreed to buy Baylis Medical for $1.75bn as it looks to expand its electrophysiology and structural heart product portfolios.
The deal will give Boston Scientific access to Baylis Medical's radiofrequency (RF) NRG and VersaCross Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access.

The company said these platforms have advanced transseptal puncture and are clinically proven to enhance safety, efficacy and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart, such as atrial fibrillation ablation, left atrial appendage closure (LAAC) and mitral valve interventions.

Baylis is expected to generate net sales of around $200m in 2022, having achieved double-digit year-over-year sales growth in each of the past five years, Boston said.

Boston Scientific chairman and chief executive Mike Mahoney said: "The talented and innovative Baylis Medical Company team, combined with these transseptal platforms, will enhance our efforts to improve procedural efficiencies with physician tools designed to make left atrial access safer and more predictable, with a focus on patient outcomes.

"A leader in many of the fastest growing markets in our industry, we believe that Baylis Medical Company will add meaningful revenue, operating income, and new research and development capabilities across multiple Boston Scientific businesses, while complementing existing offerings within our electrophysiology and structural heart portfolios."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE